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Objective:  To assess  whether  recipients  and  non-recipients  of  the  human  papillomavirus  (HPV)  vaccine
subsequently  differ  in  terms  of  sexual  risk  taking  behaviour.
Design:  Cross-sectional  survey.  Sequential  analyses  constructed  from  self-reported  age  at  vaccination,
age at  ﬁrst  intercourse  and  age at response.
Setting:  A  random  selection  of women  aged  18–46  years  living  in  Denmark,  Norway  and  Sweden  in
2011–2012,  eligible  for opportunistic  or organized  catch-up  HPV  vaccination.
Participants:  A  total  of  3805  women  reported  to  have  received  the  HPV  vaccine  and 40,247  reported
not  to have  received  it.  Among  vaccinees,  1539  received  the  HPV  vaccine  before  or at  the  same  age  as
sexual  debut,  of  which  476  and  1063 were  eligible  for organized  catch-up  and  opportunistic  vaccination,
respectively.
Main  outcome  measures:  Self-reported  sexual  behaviour,  compared  by hazard  ratios  and  odds  ratios  for
women  who  received  the  HPV  vaccine  before  or  at the  same  age  as  sexual  debut  versus  women  who  did
not receive  the  HPV  vaccine.
Results:  HPV  vaccination  did  not  result  in younger  age at ﬁrst  intercourse.  Women  who  received  the
HPV  vaccine  before  or at the  same  age  as  sexual  debut  did  not  have more  sexual  partners  than  did  non-
vaccinees.  Non-use  of  contraception  during  ﬁrst intercourse  was  more  common  among  non-vaccinees
than  among  HPV  vaccinees.  The  results  were  similar  for  organized  catch-up  and  opportunistic  vaccinees.
Conclusion:  Women  who  received  the  HPV  vaccine  before  or at the same  age  as  sexual  debut  did not
subsequently  engage  more  in sexual  risk  taking  behaviour  than  women  who  did  not receive  the  HPV
vaccine.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Human papillomavirus (HPV) can cause cervical cancer, cervi-
al preinvasive lesions and genital warts [1,2]. Clinical trials show
hat HPV vaccines effectively protect against cervical preinvasive
esions caused by the HPV vaccine types [3,4], and recent studies
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indicate that HPV vaccination already has reduced the incidence of
genital warts at the population level [5,6].
Since the HPV types that cause cervical disease are sexually
transmitted, there has been a concern that HPV vaccination may
lead to increased sexual risk-taking [7,8], which has attracted
considerable mass media attention [9]. A potential increase in
risky sexual behaviour among vaccinees may  be compensation
for a perceived reduction in risk of infection (risk compensation;
[10,11]). Some girls may  also perceive parental consent to HPV vac-
cination as authorization for sexual activity [12]. A large Swedish
survey conducted in 2007 showed that 11% of parents worried
that their child would have more unprotected sex or more part-
ners if vaccinated against HPV, and a further 21% were undecided
to the same question [13]. The concern that HPV vaccination may
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ncrease sexual risk taking may  be a barrier to HPV vaccine uptake
14].
Previous studies have shown that most girls do not intend to
hange their sexual behaviour if vaccinated against HPV [15,16].
everal recent studies indicate that the sexual behaviour of recip-
ents and non-recipients of the HPV vaccine is similar [17–22],
hich is also supported by a study addressing outcomes related to
exual activity [23]. However, studies with large population-based
amples and analyses that exclusively address sexual behaviour
ccurring subsequent to HPV vaccination are lacking. Further inves-
igations of potential associations between HPV vaccination and
exual behaviour are thus important to address the concerns
xpressed by some of those involved in decisions regarding HPV
accination.
In the present study, we investigate whether women vaccinated
gainst HPV before or at the same age as sexual debut differ from
nvaccinated women in terms of subsequent sexual risk taking
ehaviour. We  address age at ﬁrst intercourse, non-use of contra-
eption during ﬁrst intercourse and the number of sexual partners
mong women in Denmark, Norway and Sweden in the settings of
pportunistic vaccination and organized catch-up vaccination.
. Methods
.1. Study population
A total sample of 83,720 women aged 18–45 was randomly
elected from the population registries in Denmark, Norway and
weden in 2011 (Table 1). Nordic population registries contain
emographics about the entire population in the respective coun-
ry, such as each citizen’s date of birth, sex, vital status and address
24,25]. The population registries are continually updated, and each
itizen is identiﬁable by a unique personal identity number (PIN).
ll sampled women were invited to take part in the study, but
167 women were not eligible because they: did not speak the
ocal language (n = 1173), lived abroad during the time interval of
esponse (n = 696), had a physical/mental disability (n = 120), died
efore contact (n = 11), or had an unknown address (n = 1167).
Among the 80,553 women eligible for the study, 48,870
nswered the questionnaire. We  excluded 82 women due to a dis-
repancy between the registered PIN and the reported year of birth,
iving a total of 48,788 study participants, and an overall partici-
ation rate of 60.6% (Table 1). Due to a lag between sampling and
esponse, 158 women were 46 years old at response.
.2. Data collectionAn invitation to participate in the study and a self-administered
tructured questionnaire was sent to all sampled women. The
urvey could be answered by paper, web or phone. Survey data
as collected between October 2011 and October 2012. We
able 1
urvey participation.
Denmark 
Sampling and participation
Sampled (n) 26,000 
Ineligible (n) 1205 
Eligible (n) 24,795 
Participated (n) 18,631 
Participation rate (%) 75.1 
Participation by mode of response
Paper, n (%)a 10,765 (57.8) 
Web,  n (%)a 3375 (18.1) 
Phone, n (%)a 4491 (24.1) 
a Percentage among participants in each country in parentheses.2 (2014) 4945–4953
further obtained individual sociodemographic data from Statistics
Denmark, Statistics Norway and Statistics Sweden for all sampled
women. We  were permitted to use sociodemographic registry
data for comparisons of participants and non-participants only.
Further details about data collection and the questionnaire can
be found in Appendix.
2.3. HPV vaccination
HPV vaccination has been available in Denmark, Norway and
Sweden since 2006. During 2009–2012, all countries initiated
organized free of charge mass-vaccination against HPV, primarily
targeting prepubescent girls. Denmark and Sweden also offer orga-
nized catch-up vaccination of older birth cohorts, and Sweden has
subsidized opportunistic vaccination of adolescent girls. Norway
has no catch-up program. For the participants in this study, orga-
nized catch-up vaccination was  available only for Danish women
born in 1993 or 1994. For a detailed account of HPV vaccination
policies in the Nordic countries, see Sander et al. [26].
In total, 3827 women reported ever having received the HPV
vaccine and 40,247 women reported never having received it. We
excluded women  who reported an age at vaccination that was
incongruent with age at response or the year of vaccine licen-
sure/vaccine clinical trial initiation (n = 22). Thus, 3805 women
were classiﬁed as recipients of the HPV vaccine in the survey, of
which 3726 also reported age at vaccination and age at sexual
debut. Women  who reported that they did not know whether or
not they had received the HPV vaccine (n = 4234) or did not answer
the vaccine question (n = 480) were excluded from all analyses.
We deﬁned the following vaccination statuses for use in the sta-
tistical models: unvaccinated; vaccinated opportunistically before
or at the same integer age as sexual debut; vaccinated in an orga-
nized catch-up program before or at the same integer age as sexual
debut. Opportunistic vaccinees did not receive the HPV vaccine in
an organized program. Organized vaccinees were eligible for indi-
vidual invitation to free of charge HPV vaccination as part of an
organized public catch-up program. Among the 1539 women  who
received the vaccine before or at the same integer age as sexual
debut, 476 were eligible for organized vaccination and 1063 were
vaccinated opportunistically.
2.4. Statistical analyses
2.4.1. HPV vaccination and subsequent sexual debut
Although the data collection was  cross-sectional, we  could
longitudinally analyze the association between vaccination status
and age at ﬁrst intercourse by use of the reported age at vacci-
nation, age at ﬁrst intercourse and age at response. We used Cox
proportional hazards regression for the outcome of the potential
event of ﬁrst intercourse. Women  entered the model at birth and
were followed up until age at ﬁrst intercourse (non-virgins) or age
Norway Sweden Total
26,803 30,917 83,720
1570 392 3167
25,233 30,525 80,553
13,756 16,401 48,788
54.5 53.7 60.6
9580 (69.6) 11,336 (69.1) 31,681 (64.9)
2411 (17.5) 3005 (18.3) 8791 (18.0)
1765 (12.8) 2060 (12.6) 8316 (17.0)
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t response (virgins). Vaccination status was treated as a time-
ependent covariate by use of the reported age at vaccination. This
pproach allowed vaccination status and virgin/non-virgin status
o change with age, so that the distribution of rates of sexual debut
mong vaccinated and unvaccinated women could be compared
ongitudinally. Ties were handled by the Efron approximation [27].
.4.2. HPV vaccination, subsequent number of sexual partners
nd contraceptive use
The number of sexual partners was analyzed by cumulative
rdered logit models with four categories in the outcome variable
28]. For number of partners before age 18, the cutpoints separating
he ordered categories were: 1, 2 and 4 partners. For lifetime num-
er of partners, the cutpoints were: 1, 4 and 11 partners. The models
ere ﬁtted with nonproportional odds, and give probabilities for
aving more versus fewer partners at each cutpoint. Non-use of
ontraception at ﬁrst intercourse was analyzed by logistic regres-
ion.
HPV vaccination generally occurred at somewhat higher ages
han did ﬁrst intercourse (25th, 50th, 75th percentile; age at vac-
ination: 16, 18, 22; age at ﬁrst intercourse: 15, 16, 18). Moreover,
omen vaccinated before ﬁrst intercourse were relatively young
ompared to unvaccinated women (mean ± SD age at response:
9.9 ± 2.1 and 33.9 ± 7.9, respectively). To avoid confounding the
utcomes by age at response and age at ﬁrst intercourse, we
atched unvaccinated women to pre-debut vaccinees: For each
oman vaccinated before or at the same age as sexual debut, we
andomly sampled one unvaccinated woman who  was  at similar
ge at response, and who had not yet had sexual debut by the
accinee’s age at vaccination. Hence, for analyses of number of
exual partners, vaccinees as well as non-vaccinees could be vir-
in or non-virgin by the time of response. Exact matching by age
as performed whenever possible, but in a few cases the sampling
ad to be performed from a neighboring age stratum because the
upply of corresponding non-vaccinees of exactly matching age had
een exhausted. Analyses of the number of partners before age 18
ears did not include women who were vaccinated at age 18 years
r above, while analyses of lifetime number of partners and non-use
f contraceptives during ﬁrst intercourse included the full age range
f women who  were vaccinated before or at the same age as sexual
ebut. Sampling of matched non-vaccinees was done separately for
rganized and opportunistic vaccinees, and for each outcome vari-
ble. The sampling procedure resulted in groups of non-vaccinees
ith similar characteristics to the corresponding vaccinees in terms
f age at response, age at sexual debut and proportion of virgins at
esponse (Appendix, Table A.1).
.4.3. Covariates and model selection
Participants could refrain from answering any question, hence
ample size may  vary between analyses. All models were adjusted
or country (Denmark, Norway, Sweden), educational level (years
f schooling: ≤9, 10–12, 13–16, ≥16) and mode of response
able 2
azard ratiosa for earlier sexual debut, contrasting women who were and women  who w
Age at response Pre-debut HPV vaccination status n 
18–37 Unvaccinated 26,9
Vaccinated, opportunistic 10
18–24 Unvaccinated 85
Vaccinated, opportunistic 10
18–19 Unvaccinated 19
Vaccinated, organized 4
a Cox proportional hazard models with vaccination status as time-dependent covariate
b Exponentiated estimates, interpretable as multiplicative effects on the hazard relativ
c Additional covariates retained in ﬁnal models: 18–37: country, mode of response, e
evel;  18–19: country, mode of response.2 (2014) 4945–4953 4947
(paper, web, phone). Models of opportunistic vaccination were
also adjusted for the interaction between country and vaccina-
tion status. Models on the rate of sexual debut were also adjusted
for age at response and the interaction between age at response
and vaccination status. Models on the rate of sexual debut among
opportunistic vaccinees were initially restricted to women age
18–37 years at response, corresponding to the age range of oppor-
tunistic pre-debut vaccinees. Similarly, all models addressing the
effect of organized vaccination were restricted to women  age 18–19
years at response.
Non-signiﬁcant model terms were removed by backwards dele-
tion, and alternative models were compared by likelihood ratio
tests. We  also assessed models by diagnostic plots. We  report the
best ﬁtting model containing the vaccine-status variable. All tests
were two-tailed, with a 0.05 -level. Statistical computing was
done with R software [29].
3. Results
The participation rate was  highest in Denmark (75.1%), and most
women responded via the paper questionnaire (Table 1). The par-
ticipation rate was somewhat higher in the older age groups, and
among women  who  had attained higher education and income.
Participants were also more frequently married and less frequently
immigrants than were non-participants (Appendix, Table A.2–A.4).
The number of vaccinees was  lower in Norway (n = 161) than in
Denmark (n = 2508) and Sweden (n = 1057). The ofﬁcially reported
uptake rates for at least one dose of the HPV vaccine among women
eligible for organized catch-up vaccination is 87% [30]. Similarly,
87% of the women  of the corresponding cohort who  participated
in the current survey reported that they ever had received the HPV
vaccine.
3.1. HPV vaccination and subsequent sexual debut
The rates of sexual debut were similar for women who were vac-
cinated against HPV before sexual debut and unvaccinated women
(Fig. 1), and did not differ signiﬁcantly (Table 2). This held true
for opportunistic (adjusted hazard ratio (95%CI): 0.94 (0.88; 1.02))
as well as organized vaccinees (0.88 (0.76; 1.01)). Restricting the
model of opportunistic vaccination to 18–24 years olds gave a sim-
ilar result (1.07 (0.99; 1.16)). Hence, the age at ﬁrst intercourse was
similar for women  who  were vaccinated and women who were not
vaccinated against HPV.
3.2. HPV vaccination and number of subsequent partners
The number of sexual partners was not signiﬁcantly higher
among women vaccinated against HPV prior to sexual debut than
among matched unvaccinated women. Organized vaccinees did not
differ signiﬁcantly from non-vaccinees in terms of number of sex-
ual partners before age 18 or lifetime number of partners (Table 3).
ere not vaccinated against HPV prior to sexual debut.
Adjusted hazard ratiob,c 95% CIb,c Pc
18 1
55 0.94 0.88; 1.02 0.13
95 1
04 1.07 0.99; 1.16 0.10
68 1
76 0.88 0.76; 1.01 0.07
.
e to the reference level.
ducational level, age at response; 18–24: country, mode of response, educational
4948 B.T. Hansen et al. / Vaccine 32 (2014) 4945–4953
Fig. 1. Cox model estimates of the distribution of sexual debut ages, by HPV vaccination status. (A) Opportunistically vaccinated prior to sexual debut (green) versus not
vaccinated (red), age at response 18–37. (B) Vaccinated in organized catch-up program prior to sexual debut (green) versus not vaccinated (red), age at response 18–19. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 3
Comparisonsa of the number of sexual partners among women  who received the HPV vaccine through an organized catch-up program prior to sexual debut versus matchedb
unvaccinated women.
Partner comparison (p vs. q) Pre-debut HPV vaccine status Adjustedc OR (95% CI) for more partners Zc Pc
Number of partners before age 18d
≥ 1 partner vs. 0 partners Unvaccinated 1
Vaccinated 1.12 (0.85; 1.46) 0.81 0.42
≥2  partners vs. <2 partners Unvaccinated 1
Vaccinated 1.09 (0.83; 1.43) 0.63 0.53
≥4  partners vs. <4 partners Unvaccinated 1
Vaccinated 1.00 (0.71; 1.42) 0.02 0.98
Lifetime number of partnersd
≥1 partner vs. 0 partners Unvaccinated 1
Vaccinated 1.13 (0.86; 1.50) 0.90 0.37
≥4  partners vs. <4 partners Unvaccinated 1
Vaccinated 1.06 (0.78; 1.43) 0.37 0.71
≥11  partners vs. <11 partners Unvaccinated 1
Vaccinated 0.48 (0.22; 1.04) −1.86 0.06
a Cumulative ordered logit model.
b Non-vaccinees matched to vaccinees on age at response and status as virgin at age of vaccination.
c Additional covariate retained in both ﬁnal models: type of response.
d n = 466 unvaccinated; n = 466 vaccinated.
Table 4
Comparisonsa of the number of sexual partners among women who  received the HPV vaccine opportunistically prior to sexual debut versus matchedb unvaccinated women.
Partner comparison (p vs. q) Pre-debut HPV vaccine status Adjustedc OR (95% CI) for more partners Zc Pc
Number of partners before age 18d
≥1 partner vs. 0 partners Unvaccinated 1
Vaccinated 1.08 (0.88; 1.32) 0.79 0.43
≥2  partners vs. <2 partners Unvaccinated 1
Vaccinated 0.89 (0.71; 1.11) −1.04 0.30
≥4  partners vs. <4 partners Unvaccinated 1
Vaccinated 0.56 (0.40; 0.78) −3.43 0.0006
Lifetime number of partnerse
≥1 partner vs. 0 partners Unvaccinated 1
Vaccinated 1.02 (0.83; 1.26) 0.21 0.83
≥4  partners vs. <4 partners Unvaccinated 1
Vaccinated 0.93 (0.75; 1.15) −0.66 0.51
≥11  partners vs. <11 partners Unvaccinated 1
Vaccinated 1.22 (0.79; 1.86) 0.90 0.37
a Cumulative ordered logit model.
b Non-vaccinees matched to vaccinees on age at response and status as virgin at age of vaccination.
c Additional covariates retained in ﬁnal models: Pre-18 partners: education, type of response; Lifetime partners: country, type of response.
d n = 805 unvaccinated; n = 805 vaccinated.
e n = 1050 unvaccinated; n = 1050 vaccinated.
B.T. Hansen et al. / Vaccine 32 (2014) 4945–4953 4949
Table  5
Comparisonsa of non-use of any contraception during ﬁrst intercourse among women who  received the HPV vaccine prior to sexual debut versus matchedb unvaccinated
women.
Pre-debut HPV vaccine status n Crude % non-use Adjustedc,d OR (95% CI) for non-use Zd Pd
Unvaccinated 755 20.26 1
Vaccinated, opportunistic 755 14.70 0.69 (0.52; 0.93) −2.44 0.01
Unvaccinated 317 21.77 1
Vaccinated, organized 317 9.15 0.27 (0.15; 0.48) −4.41 0.00005
a Logistic regression model.
b Non-vaccinees matched to vaccinees on age at response and status as virgin at age of vaccination.
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d Additional covariates retained in ﬁnal models: opportunistic: country, type of r
pportunistic vaccinees did not differ from non-vaccinees in terms
f lifetime number of partners (Table 4), but were signiﬁcantly less
ikely than non-vaccinees to have had four or more partners before
eaching age 18 (adjusted odds ratio (95%CI): 0.56 (0.40; 0.78);
able 4). At the one and two partner cutpoints, opportunistically
accinated and unvaccinated women did not differ signiﬁcantly in
he number of partners before age 18 (Table 4).
.3. HPV vaccination and subsequent non-use of contraception
uring ﬁrst intercourse
Non-use of contraception during ﬁrst intercourse was sig-
iﬁcantly less frequent among women who received the HPV
accine before sexual debut than among matched unvaccinated
omen (Table 5). Hence, HPV vaccinees were less likely to have
n unprotected sexual debut than were non-vaccinees. The dif-
erence relative to non-vaccinees was large and highly signiﬁcant
or organized vaccinees (adjusted odds ratio (95%CI): 0.27 (0.15;
.48)), while it was less pronounced for opportunistic vaccinees
0.69 (0.52; 0.93)).
. Discussion
To our knowledge, this is the largest study to date addressing
he association between HPV vaccination and sexual behaviour in
everal countries. Since events that happen prior to HPV vaccina-
ion cannot be related to the vaccination, we investigated sexual
ehaviour occurring subsequent to vaccination. This approach
ddresses the issue of risk compensation [11] more precisely than
nalyses that do not take the sequence of vaccination and sexual
ehaviour into account. Our analyses show that women vaccinated
rior to sexual debut did not differ from unvaccinated women in
erms of age at ﬁrst intercourse or subsequent number of sexual
artners, and that they had a lower frequency of unprotected sex
t ﬁrst intercourse. This indicates that the experience of being vac-
inated against HPV does not lead to an increase in sexual risk
aking behaviour. Hence, we found no evidence of risk compen-
ation among HPV vaccinees.
We addressed sexual risk compensation separately for oppor-
unistic and organized catch-up vaccination. Further studies are
eeded to investigate whether the ﬁndings of this study also apply
o organized vaccination of prepubescent girls. Opportunistic vac-
ination has been shown to be associated with high socioeconomic
tatus [5], which is also likely to apply to our study since most
pportunistic vaccinees had to pay the entire vaccine cost. In
ontrast, organized catch-up vaccination was free of charge and
nitiated by individual invitation, and may  hence have been less
nﬂuenced by socioeconomic status. We  did not ﬁnd evidence for
exual risk compensation in any of the vaccination settings inves-
igated, which indicates that socioeconomic status did not strongly
nﬂuence our assessments of sexual behaviour by vaccination sta-
us. Note that we adjusted all analyses for educational level, ase; organized: education.
proxy for socioeconomic status that may  be associated with sexual
behaviour [31,32].
Contrary to the hypothesis of risk compensation, some of
our analyses showed that HPV vaccinees had a less risky sexual
behaviour subsequent to vaccination than did non-vaccinees. It is
conceivable that individuals with a greater awareness of sexual
health are more likely to get the HPV vaccine, or that the event of
HPV vaccination increases individual awareness of sexual health.
Individuals who seek vaccination could also be generally more risk
averse.
Previous studies also observed that HPV vaccinees do not have a
more risky sexual behaviour proﬁle than do non-vaccinees. A recent
cross-sectional survey of Australian university students showed
that women  vaccinated against HPV engaged in safe sex behaviour
to the same extent as non-vaccinated women [19]. Similarly, US
women did not differ by HPV vaccination status in terms of age at
ﬁrst sex or number of lifetime sex partners. The same study showed
that young vaccinees in fact were more likely than non-vaccinees
to use condoms [20]. Forster et al. [18] longitudinally surveyed
women eligible for organized catch-up vaccination at seven UK
schools and found no association between HPV vaccination status
and condom use or number of sexual partners. A recent study also
showed that the risk of sexual activity-related outcomes (a com-
posite variable of pregnancy, sexually transmitted infections and
contraceptive counseling) did not differ by vaccination status of
girls eligible for HPV vaccination at age 11–12 [23].
We had a relatively high participation rate, especially consid-
ering the intimate nature of some study questions. Since
non-participation still may  limit the generalizability of our ﬁndings,
we compared sociodemographic characteristics of participants
and non-participants. We  generally found modest differences.
However, participants were somewhat older, had a higher socio-
economic status and were less likely to be of immigrant origin than
non-participants. To adjust for potential confounding with vaccina-
tion status, we included several covariates in our statistical models,
such as age, country and educational level. In some models, we also
included interaction terms to test whether any effect of vaccination
status differed by country or by age. Non-participation could affect
assessment of the study hypothesis if it differed by vaccination
status. Since the vaccination status interaction terms were non-
signiﬁcant in all models, the observed differences in participation
rates by age and by country probably did not lead to differences in
the effect of vaccination status on sexual behaviour, which suggests
that non-participation did not strongly affect the main conclusion
of no sexual risk compensation among HPV vaccinees. Moreover,
the HPV vaccine uptake rate obtained by self-report from survey
participants eligible for organized catch-up vaccination reﬂected
the ofﬁcially registered uptake rate in the population, suggesting
high representativeness of this survey data. Similar comparisons for
opportunistic HPV vaccination were not reported because registry
data of HPV vaccinations taken outside the organized programs has
lower quality.
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The cross-sectional survey design limits the opportunity to
ddress causality. Another limitation of the present study is the use
f self-reported data. Misclassiﬁcation of vaccination status may
ave occurred, and self-report of sexual behaviour may  be subject
o social desirability bias [33]. Moreover, the analyses concerning
rganized catch-up vaccination only included vaccinees from
enmark, which may  limit the generalizability of the results.
Age affected most of the sexual behaviour variables in the
resent study and was differently distributed across vaccination
ategories. We  took this into account by longitudinal modelling, age
djustment, matching, and age restriction. We  also included analy-
es of the number of partners before age 18, which ensured that all
espondents had the same time interval available to gain partners
ince all survey participants were at least 18 years old. Still, the pos-
ibility of residual confounding by age cannot be entirely excluded
or the analyses that included women of a wide age range. It is thus
eassuring that the main ﬁnding of this study is supported by all
nalyses, even the narrowly age restricted and the age matched
nalyses.
As yet this is the largest study to address potential differences
n sexual behaviour between HPV vaccinees and non-vaccinees.
nother strength of this study is the representativeness of the study
ample. To our knowledge, this is the ﬁrst study of HPV vaccination
nd sexual behaviour surveying large random samples drawn from
omplete population registries. Moreover, by use of reported ages,
e addressed the sequence of vaccination and sexual behaviour in
he relevant order, thus limiting the analyses to events that may  be
emporally attributable to HPV vaccination.
. Conclusions
Women  vaccinated against HPV did not engage more in sexual
isk taking behaviour than unvaccinated women. This held true for
nalyses of opportunistic as well as organized catch-up vaccina-
ion. Hence, concerns that HPV vaccination may  lead to increased
exual risk-taking seem unwarranted, at least in the vaccination
ettings investigated here. Since HPV vaccines have high efﬁcacy
nd favourable safety proﬁles, the success of HPV vaccination as a
ublic health intervention largely seems to be a matter of vaccine
ptake. Information from this study could be useful to parents and
thers involved in decisions regarding HPV vaccination, and may
hus help to increase vaccine uptake.
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Appendix A.
A.1. Data collection
The present study is part of a survey addressing various issues
related to HPV, lifestyle and health among Nordic women. Most
of the data obtained is not registered in public registries. Women
younger than 18 were not included because they were not of
age, and women older than 45 were not included because they
were more likely to have a lower prevalence of HPV infection,
and they were not in the primary target group for HPV vaccina-
tion.
The invitation letter was sent by ordinary mail and contained
information about the study as well as a self-administered struc-
tured questionnaire, which had a study number unique to each
invited woman  printed on it. The paper questionnaire could
be returned in an enclosed envelope with pre-paid postage. A
username and password unique to each invited woman were
provided for alternative response via a web-link given in the
invitation letter. If invited women had not responded within
approximately three weeks, we mailed a reminder including a
questionnaire. If they had not answered within approximately
three weeks of the reminder, we  attempted to reach them
by phone. The call served as a second reminder, and we also
offered the invited women to answer the questionnaire by phone.
The questions posed on paper, web and phone were identi-
cal.
A.2. Questionnaire
The questionnaire contained questions on demographics, smok-
ing history, alcohol intake, reproductive history, contraceptive use,
sexual behaviour, history of sexually transmitted infections and
HPV vaccination status. The questionnaire was only provided in
Danish, Norwegian or Swedish (in the respective country).The main sexual behaviour questions relevant for the present
analyses were: (1) Have you ever had sexual intercourse? (2) If yes,
please tell us your age when you ﬁrst had sexual intercourse. (3)
Thinking back over your whole life, with how many partners have
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ou had sexual intercourse? (4) How many partners did you have
exual intercourse with before age 18? (5) What kind of contracep-
ive measure did you use at your ﬁrst sexual intercourse? The latter
uestion had seven answer options: no contraception, condom,
ormonal contraceptives, safe periods, withdrawal, morning after
ill, others. A participant was considered a non-user of contracep-
ion during ﬁrst intercourse if the option no contraception was
able A.1
haracteristics of vaccinated women and matcheda unvaccinated women.
Response variable
in analyses
HPV vaccine status nb
Number of partners
before age 18
Vaccinated, organized 466 
Matched unvaccinated 466 
Vaccinated, opportunistic 805 
Matched unvaccinated 805 
Lifetime number of
partners
Vaccinated, organized 466 
Matched unvaccinated 466 
Vaccinated, opportunistic 1050 
Matched unvaccinated 1050 
Non-use of
contraception during
ﬁrst intercourse
Vaccinated, organized 317 
Matched unvaccinated 317 
Vaccinated, opportunistic 755 
Matched unvaccinated 755 
a Matching criteria: age at response, and age at sexual debut (if any) same as or later th
b Only includes women  with answers to all questions relevant for subsequent analyses
c Women  answering the question of contraception use during ﬁrst intercourse could n
able A.2
ociodemographic characteristics of Norwegian survey participants and non-participants
Participants 
na %
Age at invitation 18–24 2935 2
25–29  2155 1
30–34  2381 1
35–39  2771 2
40–45  3514 2
Total  13,756 
Educationb Primary 1789 1
Secondary 4822 3
University 7002 5
Total  13,613 
Civil status Unmarried 7166 5
Married/cohabiting 5405 3
Divorced/separated 1070 
Otherc 53 
Total  13,694 
Incomed <100,000 1934 1
100,000–199,999 2400 1
200,000–299,999 4064 2
300,000+ 5358 3
Total  13,756 
Immigrant status Norwegiane 11,208 8
Immigrant 1587 1
Otherf 961 
Total  13,756 
a Sample size varies between variables due to missing values.
b Highest attained education.
c Same-sex partnership, divorced partnership or widow.
d Norwegian kroner (NOK), after tax.
e Born in Norway by Norwegian parents.
f Born in Norway by immigrant parent(s) or born abroad by Norwegian parents.2 (2014) 4945–4953 4951
chosen (even if additional options also were chosen), or if only safe
periods, withdrawal or morning after pill was  chosen.
The survey questions regarding vaccination status were: (1)
Have you ever been vaccinated against HPV? (options: “no”, “don’t
know” and “yes”). (2) If yes, please tell us your age when you
received the vaccination.
Tables A.1–A.4.
Age at response
(mean ± SD)
Age at ﬁrst intercourse
(mean ± SD)
Proportion of virgins at
response (% ± SD)c
18.6 ± 0.3 16.0 ± 1.1 31.3 ± 10.0
18.7 ± 0.4 16.1 ± 1.1 33.2 ± 10.2
19.8 ± 1.0 16.8 ± 1.3 23.2 ± 12.0
19.8 ± 1.1 16.7 ± 1.3 28.9 ± 12.9
18.6 ± 0.3 16.0 ± 1.1 31.3 ± 10.0
18.7 ± 0.4 16.1 ± 1.1 33.7 ± 10.2
20.6 ± 2.3 17.5 ± 2.1 27.7 ± 14.5
20.5 ± 2.0 17.5 ± 2.0 29.7 ± 14.8
18.6 ± 0.3 16.0 ± 1.1 0
18.7 ± 0.4 16.1 ± 1.1 0
20.6 ± 2.1 17.5 ± 2.1 0
20.5 ± 1.8 17.4 ± 1.8 0
an age at vaccination of vaccinee.
.
ot be virgins.
.
Non-participants
 (95% CI) na % (95% CI)
1.3 (20.7–22.0) 3553 27.2 (26.5–28.0)
5.7 (15.1–16.3) 2395 18.4 (17.7–19.0)
7.3 (16.7–18.0) 2189 16.8 (16.1–17.4)
0.1 (19.5–20.8) 2215 17.0 (16.3–17.6)
5.5 (24.8–26.3) 2695 20.7 (20.0–21.4)
13,047
3.1 (12.6–13.7) 3232 26.4 (25.6–27.2)
5.4 (34.6–36.2) 4664 38.0 (37.2–38.9)
1.4 (50.6–52.3) 4363 35.6 (34.7–36.4)
12,259
2.3 (51.5–53.2) 7582 59.1 (58.2–60.0)
9.5 (38.6–40.3) 4026 31.4 (30.6–32.2)
7.8 (7.4–8.3) 1158 9.0 (8.5–9.5)
0.4 (0.3–0.5) 63 0.5 (0.4–0.6)
12,829
4.1 (13.5–14.7) 2621 20.1 (19.4–20.8)
7.4 (16.8–18.1) 3079 23.6 (22.9–24.3)
9.5 (28.8–30.3) 3985 30.6 (29.8–31.4)
9.0 (38.1–39.8) 3357 25.7 (25.0–26.5)
13,042
1.5 (80.8–82.1) 9120 69.9 (69.1–70.7)
1.5 (11.0–12.1) 2945 22.6 (21.9–23.3)
7.0 (6.6–7.4) 981 7.5 (7.1–8.0)
13,046
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Table A.3
Sociodemographic characteristics of Danish survey participants and non-participants.
Participants Non-participants
na % (95% CI) na % (95% CI)
Age at invitation 18–24 4668 25.1 (24.4–25.7) 2185 29.7 (28.6–30.7)
25–29  2482 13.3 (12.8–13.8) 1296 17.6 (16.7–18.5)
30–34 2895 15.5 (15.0–16.1) 1106 15.0 (14.2–15.8)
35–39  3773 20.3 (19.7–20.8) 1191 16.2 (15.3–17.0)
40–45 4813 25.8 (25.2–26.5) 1591 21.6 (20.7–22.5)
Total  18,631 7369
Educationb Basic 3259 18.0 (17.4–18.5) 1958 32.2 (31.0–33.4)
High  school 3134 17.3 (16.7–17.8) 1042 17.1 (16.2–18.1)
Vocational 4720 26.0 (25.4–26.6) 1586 26.1 (25.0–27.2)
Higher 7038 38.8 (38.1–39.5) 1496 24.6 (23.5–25.7)
Total  18,151 6082
Civil  status Unmarried 9417 50.6 (49.9–51.3) 4321 59.9 (58.7–61.0)
Married 8066 43.3 (42.6–44.1) 2381 33.0 (31.9–34.1)
Divorced 1010 5.4 (5.1–5.8) 473 6.6 (6.0–7.1)
Otherc 116 0.6 (0.5–0.8) 42 0.6 (0.4–0.8)
Total  18,609 7217
Incomed <100,000 4158 22.3 (21.7–22.9) 2557 34.7 (33.6–35.8)
100,000–199,000 5892 31.6 (31.0–32.3) 2707 36.8 (35.7–37.9)
200,000–299,000 6336 34.0 (33.3–34.7) 1620 22.0 (21.1–23.0)
300,000+ 2245 12.0 (11.6–12.5) 480 6.5 (6.0–7.1)
Total  18,631 7364
Immigrant status Danishe 16,742 90.0 (89.5–90.4) 4847 67.2 (66.1–68.2)
Immigrantf 1602 8.6 (8.2–9.0) 2122 29.4 (28.4–30.5)
Descendantg 265 1.4 (1.3–1.6) 248 3.4 (3.0–3.9)
Total  18,609 7217
a Sample size varies between variables due to missing values.
b Highest attained education.
c Same-sex partnership, divorced same-sex partnership or widow.
d Danish kroner (DKK) after tax.
e At least one Danish parent.
f Born abroad, no Danish parent.
g Born in Denmark, no Danish parent.
Table A.4
Socio-demographic characteristics of Swedish survey participants and non-participants.
Participants Non-participants
na % (95% CI) na % (95% CI)
Age at invitationb 18–24 4214 25.69 (25.02–26.36) 3974 27.38 (26.65–28.10)
25–29  2641 16.10 (15.54–16.67) 2585 17.81 (17.19–18.43)
30–34  2749 16.76 (16.19–17.33) 2371 16.33 (15.73–16.94)
35–39  2996 18.27 (17.68–18.86) 2485 17.12 (16.51–17.73)
40–45  3801 23.18 (22.53–23.82) 3101 21.36 (20.70–22.03)
Total 16,401 14,516
Educationc Primary 2870 17.50 (16.92–18.08) 3858 26.59 (25.88–27.31)
Secondary 5484 33.44 (32.71–34.16) 5182 35.72 (34.94–36.50)
Post-secondary 2507 15.29 (14.73–15.84) 1852 12.77 (12.22–13.31)
University 5405 32.96 (32.24–33.67) 3069 21.16 (20.49–21.82)
Other 135 0.82 (0.68–0.96) 546 3.76 (3.45–4.07)
Total 16,401 14,507
Civil  statusd Unmarried 9785 59.66 (58.91–60.41) 9105 62.76 (61.98–63.55)
Married/cohabiting 5737 34.98 (34.25–35.71) 4264 29.39 (28.65–30.13)
Divorced/separated 845 5.15 (4.81–5.49) 1106 7.62 (7.19–8.06)
Other 34 0.21 (0.14–0.28) 32 0.22 (0.14–0.30)
Total 16,401 14,507
Incomee <100.000 6223 37.94 (37.20–38.69) 6850 47.22 (46.41–48.03)
100,000–199,999 2794 17.04 (16.46–17.61) 2357 16.25 (15.65–16.85)
200,000–299,999 4027 24.55 (23.89–25.21) 3116 21.48 (20.81–22.15)
300,000 + 3357 20.47 (19.85–21.09) 2184 15.05 (14.47–15.64)
Total 16,401 14,507
Immigrant statusf Swedish 11,987 73.09 (72.41–73.77) 8720 60.11 (59.31–60.91)
Immigrant 2410 14.69 (14.15–15.24) 3802 26.21 (25.49–26.92)
Other 2004 12.22 (11.72–12.72) 1985 13.68 (13.12–14.24)
Total 16,401 14,507
a Sample size varies between variables due to missing values.
b Calculated as birthyear subtracted from 2011.
c Post-secondary includes non-speciﬁed higher education, non-university higher education, and higher education without ﬁnal exam. Other includes unknown educational
attainment status.
d Other includes widow/widower after marriage or partnership.
e Income before taxes.
f Swedish includes born in Sweden by Swedish parents. Other born in Sweden by immigrant parent(s), or born outside Sweden with Swedish parents.
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